Asunaprevir (Standard)

Asunaprevir (Standard) is the analytical standard of Asunaprevir. This product is intended for research and analytical applications. Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM[1]. Asunaprevir inhibits SARS-CoV-2 3CLpro activity[5].

Product Specifications

CAS Number

[630420-16-5]

UNSPSC

12352100

Target

HCV; HCV Protease; Reference Standards; SARS-CoV

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Field of Research

Infection

Smiles

ClC1=CC=C2C(C(O[C@H]3CN(C([C@@H](NC(OC(C)(C)C)=O)C(C)(C)C)=O)[C@H](C(N[C@@]4(C(NS(C5CC5)(=O)=O)=O)[C@H](C=C)C4)=O)C3)=NC=C2OC)=C1

Molecular Formula

C35H46ClN5O9S

Molecular Weight

748.29

References & Citations

[1]Pelosi LA, et al. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor BMS-790052.  Antimicrob Agents Chemother. 2012 Jul 30.|[2]McPhee F, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032) . Antimicrob Agents Chemother. 2012 Aug 6.|[3]McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012 Jul;56 (7) :3670-81.|[4]Pasquinelli C, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr;56 (4) :1838-44.|[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.